Evidence map›Paper›PMID 40503897›Full record

ArticlemBio2025

KSHV reprograms host RNA splicing via FAM50A to activate STAT3 and drive oncogenic cellular transformation.

Shenyu Sun, Ling Ding, Karla Paniagua, Xian Wang, Yufei Huang, Mario A Flores, Shou-Jiang Gao

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Shenyu SunCancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Ling DingCancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Karla PaniaguaDepartment of Electrical and Computer Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Xian WangCancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Yufei HuangCancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Mario A FloresDepartment of Electrical and Computer Engineering, University of Texas at San Antonio, San Antonio, Texas, USA.
Shou-Jiang GaoCancer Virology Program, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6194-1742

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Cell Model for KSHV Infection and Genetic ManipulationR01CA096512 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Shou-Jiang Gao · 2003 to 2026
$7.4M
Regulation of KSHV replication by N6-methyladenosine (m6A) - Diversity SupplementR01CA124332 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GAO, SHOU-JIANG · 2007 to 2025
$5.0M
Impact of microbiota on AIDS-Kaposi’s sarcoma development and therapyR01CA284554 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shou-Jiang Gao · 2023 to 2026
$3.1M
Citrulline-urea cycle in KSHV cellular transformationR01CA278812 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shou-Jiang Gao · 2023 to 2026
$2.1M
METTL16 and S-adenosylmethionine cycle in KSHV infectionR01CA291244 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shou-Jiang Gao · 2025 to 2026
$1.3M
NCI NIH HHS CA096512NCI NIH HHS CA124332NCI NIH HHS CA278812NCI NIH HHS CA284554NCI NIH HHS CA291244NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA096512NCI NIH HHS R01 CA124332NCI NIH HHS R01 CA278812NCI NIH HHS R01 CA284554NCI NIH HHS R01 CA291244
6 · The paper itself

Abstract

RNA alternative splicing is a fundamental cellular process implicated in cancer development. Kaposi's sarcoma-associated herpesvirus (KSHV), the etiological agent of multiple human malignancies, including Kaposi's sarcoma (KS), remains a significant concern, particularly in AIDS patients. A CRISPR-Cas9 screening of matched primary rat mesenchymal stem cells (MM) and KSHV-transformed MM cells (KMM) identified key splicing factors involved in KSHV-induced cellular transformation. To elucidate the mechanisms by which KSHV-driven splicing reprogramming mediates cellular transformation, we performed transcriptomic sequencing, identifying 131 differentially alternative spliced transcripts, with exon skipping as the predominant event. Notably, these transcripts were enriched in vascular permeability, multiple metabolic pathways, and ERK1/2 signaling cascades, which play key roles in KSHV-induced oncogenesis. Further analyses of cells infected with KSHV mutants lacking latent genes, including vFLIP, vCyclin, and viral miRNAs, as well as cells overexpressing LANA, revealed their involvement in alternative splicing regulation. Among the identified splicing factors, FAM50A, a component of the spliceosome complex C, was found to be crucial for KSHV-mediated transformation. FAM50A knockout resulted in distinct splicing profiles in both MM and KMM cells and significantly inhibited KSHV-driven proliferation, cellular transformation, and tumorigenesis. Consistently, FAM50A knockdown suppressed the proliferation of PEL cells. Mechanistically, FAM50A knockout altered SHP2 splicing, promoting an isoform with enhanced enzymatic activity that led to reduced STAT3 Y705 phosphorylation in KMM cells. These findings reveal a novel paradigm in which KSHV hijacks host splicing machinery, specifically FAM50A-mediated SHP2 splicing, to sustain STAT3 activation and drive oncogenic transformation.IMPORTANCEKaposi's sarcoma-associated herpesvirus (KSHV) causes cancers such as Kaposi's sarcoma, particularly in AIDS patients. This study uncovers how KSHV hijacks a fundamental cellular process called RNA splicing to promote cancer development. We identified key splicing events that alter critical pathways involved in vascular permeability, metabolism, and oncogenic signaling, particularly ERK1/2 and STAT3. A specific protein, FAM50A, was found to be essential for KSHV-driven cancerous transformation. Removing FAM50A disrupted splicing, weakening cancer-promoting signals. These findings provide new insights into how viruses manipulate host cells to drive cancer and highlight RNA splicing as a potential target for future therapies.

Indexed as

Cell Transformation, NeoplasticCell Transformation, ViralHerpesvirus 8, HumanHost-Pathogen InteractionsRNA SplicingSTAT3 Transcription FactorAlternative SplicingAnimalsHumansMesenchymal Stem CellsRatsSarcoma, KaposiSTAT3 protein, humanSTAT3 Transcription Factorcellular transformationFAM50AKaposi’s sarcoma-associated herpesvirus, KSHVKaposi’s sarcoma (KS)RNA splicingSHP2STAT3 activation

Identifiers

PMID40503897
PMCPMC12239556

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.